Health Care

Insider buy signals insider confidence in PLURI Inc., as owner Weinstein adds 641 shares and backs the ZEO ScientifiX partnership—an intriguing chance for long‑term biotech investors.

Insider buying spurs optimism for Quoin Pharmaceuticals as rare‑disease drugs Q‑001 and Q‑002 approach Phase III and regulatory milestones, hinting at future upside.

Insider sales at PACS Group stay routine in the bull market, with CEO Murray Hulse’s recent 10b5‑1 sell showing no warning and the stock’s fundamentals remain strong.

Insightful analysis of HEARTFLOW Inc.’s 10b5‑1 insider trades reveals disciplined buying and strategic selling amid a rising 48% YTD stock rally, underscoring confidence in its cardiovascular pipeline and market position.

Insight into Charles River Labs’ insider trades shows a disciplined 10b5‑1 plan amid a 21% rally, highlighting strong contract pipeline and investor confidence.

Prothena insider buying: SCULLY WILLIAM P adds 100k shares, boosting stake to 27% – a bullish sign amid price dips, pipeline hype & potential catalysts.

Insider buying heats up ANIXA BIOSCIENCES—Titterton Lewis H. Jr. buys 8,000 shares at $2.98 amid a 12.26% weekly gain, 30.9% YTD volatility, and rising buzz.

Inside Acrivon’s latest insider sale: Miller Mary’s tax‑withholding trade shows steady executive confidence while the company’s proteomics pipeline drives future value.

Insider sale: ResMed’s Global General Counsel sells 400 shares under a Rule 10b5‑1 plan—no market shock, just disciplined, compliant risk management.

EXOZYMES insider purchase shows cautious optimism amid biotech volatility – a key insight for investors eyeing near‑term pipeline and market‑access milestones.